Previous 10 | Next 10 |
2023-03-08 10:51:52 ET Summary Roche has logged a few clinical successes lately, but hasn't scored the sort of big wins that change investment theses or drive lasting changes in sentiment. Fourth quarter pharmaceutical sales were fine, and Roche has a strong roster of $1B-plus/yea...
2023-03-07 06:39:11 ET Regeneron Pharmaceuticals ( NASDAQ: REGN ) and Sanofi ( NASDAQ: SNY ) announce that the FDA has accepted for review the supplemental Biologics License Application (sBLA) for Dupixent (dupilumab) to treat adults and adolescents aged 12 ye...
TARRYTOWN, N.Y. and PARIS, March 07, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) for Dupixent ® (dupilumab...
2023-03-06 16:23:07 ET Regeneron Pharmaceuticals, Inc. (REGN) Cowen 43rd Annual Health Care Conference March 6, 2023 12:50 PM ET Company Participants Marion McCourt - EVP of Commercial Ryan Crowe - Vice President & Head of IR Conference Call Participants ...
2023-03-06 13:45:59 ET Phase 2b data for Merck's ( NYSE: MRK ) oral PCSK9 inhibitor MK-0616 has prompted the drugmaker to begin a phase 3 program in the second half of the year. Results from the mid-stage trial found that at week 8 for all four dose levels, LDL-C was ...
2023-03-06 03:11:42 ET Summary In Q4 2022, the company's revenue was $24.29 billion, up 1.9% from the last three months of 2021, despite a significant decrease in people's desire to vaccinate against COVID-19. According to the Wall Street Journal, Pfizer's management is in talks t...
2023-03-05 07:14:56 ET Summary Shares of ophthalmology concern Unity Biotechnology are down some 90% since our last look in March 2021 as a news vacuum following a failed Phase 2 trial in October. That said, the company was able to leverage good interim data from its only clinical...
Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes trading in ...
Three times more patients treated with Kevzara achieved sustained remission compared to placebo in Phase 3 trial Kevzara now approved to treat two chronic inflammatory disorders TARRYTOWN, N.Y. and CAMBRIDGE, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc....
Bayer's ( OTCPK:BAYRY ) ( OTCPK:BAYZF ) Q4 earnings and sales were driven by Crop Science and Consumer Health but Pharmaceuticals saw a decline. Meanwhile, the company noted that it expects FY 2023 earnings to be below previous year due to inflation and price factors. Q4...
News, Short Squeeze, Breakout and More Instantly...
Regeneron Pharmaceuticals Inc. Company Name:
REGN Stock Symbol:
NASDAQ Market:
Regeneron Pharmaceuticals Inc. Website:
A look at the top 10 most actives in the United States Qualigen Therapeutics Inc. (QLGN) rose 111.4% to $0.4341 on volume of 412,713,755 shares Maxeon Solar Technologies Ltd. (MAXN) fell 1.3% to $0.2375 on volume of 280,800,277 shares NVIDIA Corporation (NVDA) rose 1.4% to $129.24 on volu...
2024-07-12 11:00:05 ET Trung Huynh from UBS issued a price target of $1,250.00 for REGN on 2024-07-12 10:18:00. The adjusted price target was set to $1,250.00. At the time of the announcement, REGN was trading at $1092.3075. The overall price target consensus is at $902....
A look at the top 10 most actives in the United States Maxeon Solar Technologies Ltd. (MAXN) rose 3.6% to $0.2493 on volume of 118,503,418 shares Qualigen Therapeutics Inc. (QLGN) rose 94.8% to $0.4 on volume of 100,863,101 shares AgriFORCE Growing Systems Ltd. (AGRI) rose 20.0% to $0.098...